Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials for its Prusogliptin, Dapagliflozin and Metformin extended-release tablets, a triple-drug combination therapy for adult patients with type 2 diabetes mellitus whose blood sugar is not adequately controlled with metformin alone. Billed as the world’s first clinically approved combination of these three agents, the product leverages complementary mechanisms of action to target multiple pathophysiological aspects of diabetes, promising effective glycemic control, a favorable safety and tolerability profile, and simplified treatment regimens that may improve patient adherence, while also strengthening CSPC’s presence and pipeline in the competitive metabolic disease market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong–incorporated pharmaceutical company focused on developing and commercializing innovative drugs, with a growing pipeline in metabolic diseases such as type 2 diabetes mellitus. The group develops advanced formulations aimed at improving treatment efficacy, safety and patient adherence in major chronic disease areas.
YTD Price Performance: 88.72%
Average Trading Volume: 124,058,396
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$100.9B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.